Jeff Cislini Biography and Net Worth

General Counsel of Revolution Medicines

Jeff focused on corporate law early in his career because he was looking for an opportunity to bring legal expertise to complex business challenges. The ability to meet these challenges as part of a team that directly impacts the lives of patients drew Jeff to biotech.

He has approximately 20 years of experience and brings a pragmatic approach to practicing law, striving to interpret and discuss complex legal concepts in a coherent manner that results in actionable business advice.

Jeff comes to RevMed from Atara Biotherapeutics, where he most recently served as a Vice President and had responsibility for a broad range of legal matters, including corporate, contracts and employment. Prior to Atara, Jeff worked for a number of years as outside counsel focused on general corporate representation and transactional advice at the law firms of O’Melveny & Myers and Wilson Sonsini Goodrich & Rosati.

Jeff holds a JD from Harvard Law School and a BAS from Stanford University with dual majors in Land Resources Planning and Economics. He is a member of the California bar.

What is Jeff Cislini's net worth?: The estimated net worth of Jeff Cislini is at least $1.70 million as of October 11th, 2024. Mr. Cislini owns 45,634 shares of Revolution Medicines stock worth more than $1,704,430 as of March 29th. This net worth approximation does not reflect any other investments that Mr. Cislini may own. Learn More about Jeff Cislini's net worth.
How do I contact Jeff Cislini?: The corporate mailing address for Mr. Cislini and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at ir@revmed.com. Learn More on Jeff Cislini's contact information.
Has Jeff Cislini been buying or selling shares of Revolution Medicines?: Jeff Cislini has not been actively trading shares of Revolution Medicines in the last ninety days. Most recently, Jeff Cislini sold 6,000 shares of the business's stock in a transaction on Friday, October 11th. The shares were sold at an average price of $50.17, for a transaction totalling $301,020.00. Following the completion of the sale, the general counsel now directly owns 45,634 shares of the company's stock, valued at $2,289,457.78. Learn More on Jeff Cislini's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 23 times. They sold a total of 241,280 shares worth more than $11,237,223.60. The most recent insider tranaction occured on March, 17th when insider Mark A Goldsmith sold 11,738 shares worth more than $458,251.52. Insiders at Revolution Medicines own 8.0% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 3/17/2025.

Jeff Cislini Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/11/2024	Sell	6,000	$50.17	$301,020.00	45,634
7/9/2024	Sell	2,399	$40.83	$97,951.17	47,088
6/26/2024	Sell	2,000	$38.47	$76,940.00	49,487
3/27/2024	Sell	1,500	$30.99	$46,485.00	54,374
3/18/2024	Sell	1,252	$31.58	$39,538.16	55,874
1/22/2024	Sell	1,500	$27.00	$40,500.00	36,126
12/18/2023	Sell	1,229	$25.90	$31,831.10	37,284
11/20/2023	Sell	1,500	$21.70	$32,550.00	38,513
9/28/2023	Sell	2,000	$28.20	$56,400.00	40,013
9/18/2023	Sell	1,214	$31.31	$38,010.34	42,013
7/31/2023	Sell	1,500	$26.02	$39,030.00	43,227
6/20/2023	Sell	1,239	$25.14	$31,148.46	44,727

Jeff Cislini Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $37.35

$37.03

$38.11

50 Day Range

MA: $40.32

$36.82

$44.25

2 Week Range

Now: $37.35

$29.55

$62.40

Volume

833,196 shs

Average Volume

1,375,673 shs

Market Capitalization

$6.94 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46